Should I buy or sell ACADIA Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks .

What is ACADIA Pharmaceuticals' stock price target for 2024?

12 equities research analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $15.00 to $95.00. On average, they anticipate the company's share price to reach $35.67 in the next year. This suggests a possible upside of 65.9% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts .

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD shares have increased by 35.1% and is now trading at $21.50. View the best growth stocks for 2023 here .

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our ACAD earnings forecast .

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $211.70 million for the quarter, compared to analysts' expectations of $194.40 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 38.84% and a negative net margin of 23.55%.

What ETFs hold ACADIA Pharmaceuticals' stock?

ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , ALPS Medical Breakthroughs ETF (SBIO) , Invesco Biotechnology & Genome ETF (PBE) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Biotech ETF (XBI) , Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) .

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com . Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Sarepta Therapeutics (SRPT) , Pfizer (PFE) , Tesla (TSLA) , Alibaba Group (BABA) , Amarin (AMRN) , Advanced Micro Devices (AMD) and Exelixis (EXEL) .

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (7.05%), FMR LLC (3.23%), Fred Alger Management LLC (1.89%), Morgan Stanley (1.13%), Emerald Advisers LLC (1.03%) and Jacobs Levy Equity Management Inc. (0.87%). Insiders that own company stock include Austin D Kim, Austin D Kim , Brendan Teehan , Bros Advisors Lp Baker, Elena Ridloff , James Kihara , Laura Brege , Mark C Schneyer , Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis . View institutional ownership trends .

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ACADIA Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACAD)

$20.91

-0.88 (-4.04%)

(As of 01:57 PM ET)

Compare

Today's Range: $20.87
▼
$21.73
50-Day Range: $20.78
▼
$24.07
52-Week Range: $14.48
▼
$33.99

Volume: 686,448 shs
Average Volume: 1.54 million shs
Market Capitalization: $3.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.67

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 65.9% Upside
$35.67 Price Target
Short Interest: Bearish
4.74% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.04
Based on 12 Articles This Week
Insider Trading: Selling Shares
$1.82 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.33) to $0.94 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

188th out of 960 stocks

Pharmaceutical Preparations Industry

47th out of 378 stocks

4.4

Analyst's Opinion

Consensus Rating
ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.67, ACADIA Pharmaceuticals has a forecasted upside of 65.9% from its current price of $21.50.
Amount of Analyst Coverage
ACADIA Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
4.74% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in ACADIA Pharmaceuticals has recently increased by 3.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ACADIA Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ACADIA Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACAD.

1.1

News and Social Media Coverage

News Sentiment
ACADIA Pharmaceuticals has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for ACADIA Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 6 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,816,427.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.29% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.33) to $0.94 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ACADIA Pharmaceuticals is -23.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ACADIA Pharmaceuticals is -23.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ACADIA Pharmaceuticals has a P/B Ratio of 8.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACAD Stock News Headlines

December 8, 2023 | americanbankingnews.com

Q3 2025 EPS Estimates for ACADIA Pharmaceuticals Inc. Decreased by Zacks Research (NASDAQ:ACAD)

December 8, 2023 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Increased to Buy at StockNews.com

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 6, 2023 | fool.com.au

Up 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?

December 3, 2023 | americanbankingnews.com

StockNews.com Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to Hold

December 1, 2023 | msn.com

Acadia starts Phase III study of PWS therapy

December 1, 2023 | msn.com

Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS

November 30, 2023 | msn.com

Acadia starts Phase 3 study for Prader-Willi hunger treatment

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | americanbankingnews.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Recommendation of "Moderate Buy" by Brokerages

November 28, 2023 | msn.com

Acadia Pharmaceuticals begins trial of Alzheimer’s psychosis drug

November 28, 2023 | benzinga.com

ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) Dividends: History, Yield and Dates

November 28, 2023 | finance.yahoo.com

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study

November 22, 2023 | morningstar.com

ACADIA Pharmaceuticals Inc ACAD

November 22, 2023 | finance.yahoo.com

Insider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals Inc

November 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Morphosys Ag (MOR) and Enanta Pharmaceuticals (ENTA)

November 21, 2023 | marketwatch.com

Acadia Pharmaceuticals' Research and Development Head to Exit

November 21, 2023 | finance.yahoo.com

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

November 20, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should Know

November 17, 2023 | finance.yahoo.com

Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?

November 17, 2023 | finance.yahoo.com

Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), ACADIA Pharmaceuticals (ACAD) and Personalis (PSNL)

November 7, 2023 | markets.businessinsider.com

Hold Rating on ACADIA Pharmaceuticals: Balancing Growth Potential, Discontinuation Risks, and IP Litigation Concerns

November 7, 2023 | msn.com

Mizuho Upgrades Acadia Pharmaceuticals (ACAD)

November 4, 2023 | finance.yahoo.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript

November 3, 2023 | markets.businessinsider.com

ACADIA Pharmaceuticals Earns Buy Rating: Strong Q3 Performance, Promising Pipeline, and Market Dominance Highlighted

November 3, 2023 | markets.businessinsider.com

Promising ADVANCE-2 Trial Results Bolster ACADIA Pharmaceuticals’ Buy Rating: An Analysis by Andrew Fein

See More Headlines

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACAD
CUSIP: N/A
CIK: 1070494
Web: www.acadia-pharm.com
Phone: (858) 558-2871
Fax: 858-558-2872
Employees: 580
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.67
High Stock Price Target: $95.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +63.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-215,980,000.00
Net Margins: -23.55%
Pretax Margin: -20.83%
Return on Equity: -38.84%
Return on Assets: -23.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.38
Quick Ratio: 2.28

Sales & Book Value

Annual Sales: $631.89 million
Price / Sales: 5.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 8.82

Miscellaneous

Outstanding Shares: 164,180,000
Free Float: 119,031,000
Market Cap: $3.58 billion
Optionable: Optionable
Beta: 0.59

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Stephen R. Davis J.D. (Age 62)
President, CEO & Director
Comp: $1.46M
Mr. Mark C. Schneyer (Age 49)
Executive VP & CFO
Comp: $701.03k
Mr. Brendan P. Teehan (Age 54)
Executive VP, COO & Head of Commercial
Comp: $724.31k
Mr. Austin D. Kim (Age 59)
Executive VP, General Counsel & Secretary
Comp: $722.15k
Mr. James K. Kihara (Age 42)
VP, Chief Accounting Officer & Corporate Controller
Mr. Albert S. Kildani
Senior Vice President of Investor Relations & Corporate Communications
Ms. Julie Fisher
Senior Vice President of Marketing & Commercial Strategy
Ms. Holly Valdiviez
Senior VP & Head of Sales
Mr. Rob Ackles
Senior VP & Chief People Officer
Mr. Bob Mischler
Senior Vice President of New Product Planning & Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings or view top-rated stocks.
What is ACADIA Pharmaceuticals' stock price target for 2024?: 12 equities research analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $15.00 to $95.00. On average, they anticipate the company's share price to reach $35.67 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.
How have ACAD shares performed in 2023?: ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD shares have increased by 35.1% and is now trading at $21.50.
View the best growth stocks for 2023 here.
When is ACADIA Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our ACAD earnings forecast.
How were ACADIA Pharmaceuticals' earnings last quarter?: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $211.70 million for the quarter, compared to analysts' expectations of $194.40 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 38.84% and a negative net margin of 23.55%.
What ETFs hold ACADIA Pharmaceuticals' stock?: ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?: 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.
What other stocks do shareholders of ACADIA Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).
Who are ACADIA Pharmaceuticals' major shareholders?: ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (7.05%), FMR LLC (3.23%), Fred Alger Management LLC (1.89%), Morgan Stanley (1.13%), Emerald Advisers LLC (1.03%) and Jacobs Levy Equity Management Inc. (0.87%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.
How do I buy shares of ACADIA Pharmaceuticals?: Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial